Kiniksa Pharmaceuticals International (KNSA) Accounts Payables (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Accounts Payables for 10 years, with the latest figure at $24.4 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 1131.18% year-over-year to $24.4 million; the trailing twelve-month figure through Mar 2026 stood at $24.4 million (up 1131.18% YoY), and the FY2025 full-year result was $2.0 million, down 0.54% from the prior year.
• Accounts Payables for Q1 2026 stood at $24.4 million, up from $2.0 million in the prior quarter.
• The five-year high for Accounts Payables was $24.4 million in Q1 2026, with the low at $648000.0 in Q2 2023.
• Historically, Accounts Payables has averaged $5.5 million across 5 years, with a median of $3.4 million in 2022.
• Annual changes were most pronounced in 2024 — Accounts Payables slumped 75.27% — and 2026, when it surged 1131.18%.
• Kiniksa Pharmaceuticals International's Accounts Payables stood at $7.9 million in 2022, then advanced by 4.39% to $8.2 million in 2023, then tumbled by 75.27% to $2.0 million in 2024, then declined by 0.54% to $2.0 million in 2025, then soared by 1103.25% to $24.4 million in 2026.
• The last three Accounts Payables figures came in at $24.4 million (Q1 2026), $2.0 million (Q4 2025), and $6.1 million (Q3 2025), per Business Quant data.